Voyager Therapeutics (NASDAQ:VYGR) Shares Up 1.4%

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) shares traded up 1.4% during trading on Thursday . The company traded as high as $7.88 and last traded at $7.85. 140,559 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 925,631 shares. The stock had previously closed at $7.74.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on VYGR shares. Citigroup began coverage on Voyager Therapeutics in a research note on Thursday, March 7th. They issued a "buy" rating and a $16.00 price objective for the company. Guggenheim began coverage on shares of Voyager Therapeutics in a research note on Tuesday, March 26th. They set a "buy" rating and a $22.00 price target for the company. Wells Fargo & Company raised shares of Voyager Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $9.00 to $14.00 in a research note on Tuesday, January 2nd. StockNews.com raised Voyager Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, March 9th. Finally, HC Wainwright assumed coverage on Voyager Therapeutics in a research report on Tuesday, March 19th. They issued a "buy" rating and a $30.00 price target on the stock. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $19.33.

Voyager Therapeutics Stock Down 2.5 %

The firm has a market cap of $409.97 million, a P/E ratio of 2.44 and a beta of 0.96. The stock's 50-day simple moving average is $8.80 and its 200 day simple moving average is $7.95.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $1.84. The company had revenue of $90.06 million for the quarter, compared to the consensus estimate of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. On average, research analysts forecast that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current fiscal year.

Institutional Trading of Voyager Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Gladius Capital Management LP bought a new stake in Voyager Therapeutics during the 3rd quarter worth approximately $25,000. Ameritas Investment Partners Inc. bought a new stake in Voyager Therapeutics during the second quarter worth $30,000. UBS Group AG purchased a new stake in Voyager Therapeutics in the 1st quarter valued at $39,000. AJOVista LLC bought a new position in Voyager Therapeutics during the 4th quarter valued at $39,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Voyager Therapeutics in the 4th quarter worth $43,000. Institutional investors own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.